NATURAL ANTIBODY AGAINST GROUP B STREPTOCCOUS IN MICE
NATURAL ANTIBODY AGAINST GROUP B STREPTOCCOUS IN MICE
批准号:
6226245
负责人:
PETER BUTKO
金额:
$14.27万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2004-03-31
中文摘要
描述(摘自申请人摘要):B群链球菌(GBS,
英文摘要
DESCRIPTION (Verbatim from Applicant's Abstract): Group B streptococcus (GBS,
Streptococcus agalactiae) is the most common cause of neonatal sepsis and
meningitis in the USA. A humoral factor has been discovered in normal mouse
serum which protects the animals against GBS infection. It is hypothesized that
the protective factor is natural IgM antibody. Two goals of the proposed
research are: (i) To confirm that the antibody is of the IgM type and that it
is protective against experimental GBS infections in vivo; (ii) to identify the
antigenic target for this antibody on the bacterial surface. To these aims,
several clinical isolates and mutant strains of GBS, in combination with in
vitro enzyme-linked immunosorbent assays (ELISA) and in vivo mouse protection
experiments will be utilized. Results obtained with mice as animal model may
open a new avenue of investigation into possible role of natural antibodies in
human immunity to GBS infection and bacterial infection in general, with
possible implications for immunotherapy. The results also may provide impetus
to the research on the antigenic targets on GBS, possibly other than the
capsular polysaccharide, which would have implications for current GBS vaccine
efforts. A non-scientific goal of this project is to increase the intensity of
health-related undergraduate research and teaching in a mid-size rural
university with no medical school and to increase diversity in the work force
in the academic research and medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文